ACR速递 | AS患者:控制症状外,如何应对骨的进展?( 四 )


[4] Kiltz U, et al. Arthritis Rheumatol. 2020; 72 (suppl 10). Abstract #0354.
[5] Braun J, et al. Ann Rheum Dis. 2011 Mar;70 Suppl 1: i97-103.
[6] Poddubnyy, et al. Current Rheumatology Reports.2017;19(9):55.
[7] 陈超, 等. 天津医药. 2015 , 43(10):1213-1216.
[8] Gravallese, E.M.et al. Nat Rev Rheumatol. 2018(14):631–640.
[9] Sherlock, J. P. et al. Nat. Med. 2012, 18: 1069–1076.
[10] Ebihara, S., et al. Autoimmunity. 2015, 48: 259–266.
[11] T. Russell, et al. Ann Rheum Dis, volume 79, supplement 1, year 2020, page 1117.
[12] Yago, T. et al. Arthritis Res Ther. 2007, 9: R96.
[13] Ju, J. H. et al. J Immunol. 2008, 181:1507–1518.
[14] Li, X. et al. Immunol. Lett. 2010, 127: 100–107.
[15] Chen, L., et al. Eur J Immunol. 2008, 38: 2845–2854.
[16] Shin, H. S. et al. J Immunol. 2015, 194: 316–324.
[17] Kamiya, S. et al. J. Bone Miner Metab. 2007, 25: 277–285.
[18] Quinn, J. M. et al. J Immunol. 2008, 181: 5720–5729 .
[19] Deodhar A, et al. Arthritis Rheumatol. 2019; 71: 258–70.
[20] Baeten D, et al. Ann Rheum Dis 2018; 77:1295–302.
[21] Braun J et al. Rheumatology (Oxford). 2019;58(5):859-868.
[22] Braun J, et al. Ann Rheum Dis. 2017 Jun;76(6):1070-1077
[23] van der Heijde D, et al. Rheumatology (Oxford). 2019 Mar 1;58(3):388-400.
[24] Zong HX, et al. Mod Rheumatol. 2019 May;29(3):503-509.
MCC号CXA2012249有效期2021-12-03 , 资料过期 , 视同作废 。